List view / Grid view
Researchers have developed a novel gene therapy approach that reactivates dormant genes by repositioning them closer to genetic switches called enhancers - showing promise for treating blood disorders like sickle cell disease.
Genomics laid the foundation for precision medicine, but on its own, it offers only part of the picture. This article explores how integrated multiomics can provide the deeper biological context needed to drive more effective therapies forwards.
Researchers at the University of Oklahoma have found a way to improve drugs by adding just one carbon atom. This simple change could speed up drug discovery and lower costs.
An experimental peptide from Virginia Tech may offer a new way to stop glioblastoma from coming back by disrupting the cancer’s treatment-resistant core.
A new study from the University of Barcelona’s Institute of Neurosciences has discovered a crucial role for the RTP801 protein in astrocytes, potentially making way for future therapies aimed at slowing or reversing cognitive decline.
Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.
Researchers at Moffitt Cancer Center have discovered that blocking a chemical process called nitrosylation can make aggressive NRAS-mutant melanoma more responsive to treatment.
Scientists at UT Health San Antonio have identified PSPC1 in mouse models as a promising new drug target for acute myeloid leukaemia (AML), a deadly blood cancer with limited treatment options.
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
Five distinct CRC prognostic subtypes were identified, which could revolutionise the way CRC is diagnosed and treated.
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
Molecular, cellular and metabolic analyses of liver biopsies identified markers that may predict subsequent metastasis of pancreatic cancer.
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
New study reveals how pneumonia cells become resistant to penicillin through evolutionary gateway.
